Guillain-Barre Syndrome (GBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Guillain-Barre syndrome (GBS) is a rare neurological disorder in which the body's immune system attacks its peripheral nervous system by mistake—the network of nerves located outside the brain and spinal cord. An infection often precedes Guillain-Barré syndrome. This could be a bacterial or viral infection. GBS may also be triggered by vaccine administration or surgery. In the context of Zika virus infection, an unexpected increase in cases of Guillain-Barré syndrome has been described in affected countries. The most likely explanation of evidence from outbreaks of Zika virus infection and Guillain-Barre syndrome is that Zika virus infection triggers GBS.
- The prevalence of Guillain-Barre syndrome is estimated to be 6 to 40 cases per 1 million people.
- AMAN and AMSAN together account for 30 to 50 percent of cases in Asian countries and Latin America but only 3 to 5 percent of cases in North America and Europe.
Thelansis’s “Guillain-Barre Syndrome (GBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Guillain-Barre Syndrome (GBS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Guillain-Barre Syndrome (GBS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Guillain-Barre Syndrome (GBS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment